甘李药业
(603087)
| 流通市值：325.23亿 | | | 总市值：348.23亿 |
| 流通股本：5.58亿 | | | 总股本：5.97亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 878,108,964.52 | 4,052,146,959.53 | 3,047,039,079.24 | 2,066,795,642.77 |
| 营业收入 | 878,108,964.52 | 4,052,146,959.53 | 3,047,039,079.24 | 2,066,795,642.77 |
| 二、营业总成本 | 682,007,364.82 | 3,211,492,206.21 | 2,275,937,092.07 | 1,515,608,273.35 |
| 营业成本 | 223,401,494.05 | 978,951,761.53 | 725,750,228.68 | 490,877,014.62 |
| 税金及附加 | 13,626,505.32 | 39,124,683.12 | 28,744,855.36 | 18,657,751.86 |
| 销售费用 | 270,478,075.88 | 1,350,426,822.26 | 978,990,601.81 | 656,481,754.37 |
| 管理费用 | 56,772,723.33 | 268,898,684.65 | 196,121,275.25 | 134,027,579.04 |
| 研发费用 | 128,036,994.79 | 646,974,969.22 | 407,861,819.05 | 264,523,560.46 |
| 财务费用 | -10,308,428.55 | -72,884,714.57 | -61,531,688.08 | -48,959,387 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 6,734,716.62 | 73,818,236.87 | 72,066,564.13 | 64,965,330.59 |
| 加:投资收益 | 4,510,180.34 | 290,775,382.32 | 10,823,936.85 | 7,078,197.36 |
| 资产处置收益 | -77.07 | 3,712,360.69 | - | - |
| 资产减值损失(新) | 40,670.45 | -36,125,457.82 | 876,940.21 | 18,215.12 |
| 信用减值损失(新) | 499,527.09 | -15,025,494.75 | -1,923,291.76 | -1,157,683.72 |
| 其他收益 | 5,879,914.51 | 25,862,302.72 | 15,707,102.52 | 9,513,575.34 |
| 四、营业利润 | 213,766,531.64 | 1,183,672,083.35 | 868,653,239.12 | 631,605,004.11 |
| 加:营业外收入 | 538,261.57 | 62,971,919.37 | 62,344,001.18 | 61,996,279.54 |
| 减:营业外支出 | 1,661,715.18 | 16,838,258.58 | 5,287,205.22 | 2,580,268.68 |
| 五、利润总额 | 212,643,078.03 | 1,229,805,744.14 | 925,710,035.08 | 691,021,014.97 |
| 减:所得税费用 | 20,181,036.31 | 86,222,140.86 | 107,370,417.78 | 87,340,442.49 |
| 六、净利润 | 192,462,041.72 | 1,143,583,603.28 | 818,339,617.3 | 603,680,572.48 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 192,462,041.72 | 1,143,583,603.28 | 818,339,617.3 | 603,680,572.48 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 192,485,871.22 | 1,143,583,603.28 | 818,339,617.3 | 603,680,572.48 |
| 少数股东损益 | -23,829.5 | - | - | - |
| 扣除非经常损益后的净利润 | 186,069,686.5 | 779,988,757.21 | 692,435,647.69 | 487,921,514.17 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.33 | 1.93 | 1.38 | 1.02 |
| (二)稀释每股收益 | 0.33 | 1.93 | 1.38 | 1.02 |
| 八、其他综合收益 | -565,382.71 | -973,884.42 | -406,764.76 | -21,049.12 |
| 归属于母公司股东的其他综合收益 | -565,382.71 | -973,884.42 | -406,764.76 | -21,049.12 |
| 九、综合收益总额 | 191,896,659.01 | 1,142,609,718.86 | 817,932,852.54 | 603,659,523.36 |
| 归属于母公司股东的综合收益总额 | 191,920,488.51 | 1,142,609,718.86 | 817,932,852.54 | 603,659,523.36 |
| 归属于少数股东的综合收益总额 | -23,829.5 | - | - | - |
| 公告日期 | 2026-04-23 | 2026-04-23 | 2025-10-31 | 2025-08-08 |
| 审计意见(境内) | | 标准无保留意见 | | |